Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics

D. S. Alberts, B. G.M. Durie, S. E. Salmon

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Four anticancer drugs with cell cycle phase-specific characteristics (azathioprine, cytosine arabinoside, hydroxyurea, and vincristine) were individually used to treat 12 patients with multiple myeloma in partial remission (i.e., ≥ 50% reduction in tumor cell number) after cell cycle nonspecific chemotherapy. In six of eight patients vincristine induced further statistically significant reductions in total body myeloma cell number (24%-60% tumor cell reductions), whereas, azathioprine had lesser activity. Cytosine arabinoside and hydroxyurea were unsuccessful and excessively toxic chemotherapeutic agents in this setting, although optimal dosing schedules were difficult to achieve because they caused moderately severe bone marrow suppression. We conclude that vincristine is a useful cytoreductive agent for multiple myeloma and should be added to cell cycle nonspecific agents for the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)381-388
Number of pages8
JournalCancer Treatment Reports
Volume61
Issue number3
StatePublished - Dec 1 1977

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics'. Together they form a unique fingerprint.

  • Cite this